News | August 12, 2021
Hester Biosciences posts PAT of Rs 11.01 cr in Q1FY22
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company has tied up with OrbiMed as a financial partner for global reach
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The aim is to create new genomics solutions that could combat cancer and advance market access
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
Subscribe To Our Newsletter & Stay Updated
